Nanogam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Nanogam, is an immunoglobulin presented as a solution for injection for intravenous use. It replaces deficient IgG antibodies and is used in primary and secondary immunodeficiency diseases, immune thrombocytopenic purpura, and Kawasaki disease.

GNH USA supplies Nanogam as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nanogam is an immunoglobulin replacement therapy used to address immune deficiencies and related disorders. - Primary immunodeficiency diseases: provides IgG replacement to reduce infection frequency and severity. - Secondary immunodeficiency: restores antibody levels compromised by disease or treatment. - Immune thrombocytopenic purpura (ITP): modulates immune response to increase platelet counts. - Kawasaki disease: used as adjunct therapy to lessen inflammation and prevent coronary artery complications.

Nanogam may cause a range of adverse reactions, most of which are related to the intravenous infusion process.

Common Side Effects: - Infusion‑related reactions (e.g., chills, fever, flushing) - Headache - Nausea - Fatigue

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Aseptic meningitis - Acute renal failure - Thrombotic events (e.g., deep vein thrombosis) - Hemolysis - Severe hypotension

Before initiating Nanogam therapy, clinicians should consider several safety measures. - Baseline assessment: evaluate patient’s IgG levels and renal function. - Infusion monitoring: observe for signs of reaction and adjust rate as needed. - Pre‑medication: consider antihistamines or antipyretics to reduce infusion symptoms. - Contraindication check: avoid in patients with known IgA deficiency who have anti‑IgA antibodies. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nanogam can interact with other therapies, requiring attention to avoid reduced efficacy or increased risk.

Major Interactions (Avoid): - Live vaccines: may diminish vaccine effectiveness. - Concurrent immunoglobulin products: risk of immunoglobulin overload. - Monoclonal antibodies targeting B cells: may heighten infection susceptibility.

Moderate Interactions (Monitor Closely): - Corticosteroids: may mask infusion‑related reactions. - Anticoagulants: potential for increased bleeding with IV administration. - Non‑live vaccines: possible altered immune response, monitor antibody titers.